MedTrace Logo

Blood Biomarker in Early Parkinson's Disease

NCT03384797 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 65

Last updated 2019-06-10

No results posted yet for this study

Summary

Currently, there are no cures or disease modifying therapies for Parkinson's disease (PD). This is partially due to the inability to detect the disease before it has progressed to a stage where there are clinical manifestations. The identification and validation of high throughput biomarkers to measure disease progression (as well as identify pre-clinical disease onset) is critical to the development of disease-modifying or even preventative therapies. In this study, we are testing a blood biomarker for PD. Several detection parameters will be assessed through enrollment of Parkinson's patients and age matched healthy volunteers over 50 years of age to learn more about the analytical process and biological variability.

Conditions

  • Parkinson Disease

Sponsors & Collaborators

Principal Investigators

  • Laurie Sanders, PhD · Duke University

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-01-22
Primary Completion
2019-01-07
Completion
2019-01-07

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03384797 on ClinicalTrials.gov